George S. Biggs

George S. Biggs

Auto-generated profile, based on publicly available information

George S. Biggs

Crick-GSK Biomedical LinkLabs, GSK, Gunnels Wood Road, Stevenage, Hertfordshire, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
GBGeorge S. Biggs
George S. Biggs
ECEmma E. Cawood
Emma E. Cawood
AVAini Vuorinen
Aini Vuorinen
WMWilliam J. McCarthy
William J. McCarthy
HWHarry Wilders
Harry Wilders
JBJacob T. Bush
Jacob T. Bush
Identifying pharmacological probes for human proteins represents a key opportunity to accelerate the discovery of new therapeutics. High-content screening approaches to expand the ligandable proteome offer the potential to expedite the discovery of novel chemical probes to study protein function. Screening libraries of reactive fragments by chemoproteomics offers a compelling approach to ligand discovery, however, optimising sample throughput, proteomic depth, and data reproducibility remains a key challenge. We report a versatile, label-free quantification proteomics platform for competitive profiling of cysteine-reactive fragments against the native proteome. This high-throughput platform combines SP4 plate-based sample preparation with rapid chromatographic gradients. Data-independent acquisition performed on a Bruker timsTOF Pro 2 consistently identified ~23,000 cysteine sites per run, with a total of ~32,000 cysteine sites profiled in HEK293T and Jurkat lysate. Crucially, this depth in cysteinome coverage is met with high data completeness, enabling robust identification of liganded proteins. In this study, 80 reactive fragments were screened in two cell lines identifying >400 ligand-protein interactions. Hits were validated through concentration-response experiments and the platform was utilised for hit expansion and live cell experiments. This label-free platform represents a significant step forward in high-throughput proteomics to evaluate ligandability of cysteines across the human proteome.

10 December 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
HWHarry Wilders
Harry Wilders
GBGeorge Biggs
George Biggs
SRSam M. Rowe
Sam M. Rowe
ECEmma E. Cawood
Emma E. Cawood
IRIoannis G. Riziotis
Ioannis G. Riziotis
JBJacob T. Bush
Jacob T. Bush
Reactive fragment (RF) screening has emerged as an efficient method for ligand discovery across the proteome, irrespective of a target's perceived tractability. To date, however, the efficiency of subsequent optimisation campaigns has largely been low‐throughput, constrained by the need for synthesis and purification of target compounds. We report an efficient platform for ‘direct‐to‐biology’ (D2B) screening of cysteine‐targeting chloroacetamide RFs, wherein synthesis is performed in 384‐well plates allowing direct assessment in downstream biological assays without purification. Here, the developed platform was used to optimise inhibitors of SARS‐CoV‐2 main protease (MPro), an established drug target for the treatment of COVID‐19. An initial RF hit was developed into a series of potent inhibitors, and further exploration using D2B screening enabled a ‘switch’ to a reversible inhibitor series. This example of ligand discovery for MPro illustrates the acceleration that D2B chemistry can offer for optimising RFs towards covalent inhibitor candidates, as well as providing future impetus to explore the evolution of RFs into non‐covalent ligands.

1 August 2019 in Cancer Letters
Verified
Journal Article
Open access
CLChi-Chuan Lin
Chi-Chuan Lin
KSKin Man Suen
Kin Man Suen
ASAmy Stainthorp
Amy Stainthorp
LWLukasz Wieteska
Lukasz Wieteska
GBGeorge S. Biggs
George S. Biggs
JLJohn Ladbury
John Ladbury
Receptor tyrosine kinase (RTK)-mediated hyperactivation of the MAPK/Erk pathway is responsible for a large number of pathogenic outcomes including many cancers. Considerable effort has been directed at targeting this pathway with varying degrees of long term therapeutic success. Under non-stimulated conditions Erk is bound to the adaptor protein Shc preventing aberrant signalling by sequestering Erk from activation by Mek. Activated RTK recruits Shc, via its phosphotyrosine binding (PTB) domain (ShcPTB), precipitating the release of Erk to engage in a signalling response. Here we describe a novel approach to inhibition of MAP kinase signal transduction through attempting to preserve the Shc-Erk complex under conditions of activated receptor. A library of existing drug molecules was computationally screened for hits that would bind to the ShcPTB and block its interaction with the RTKs EGFR and ErbB2. The primary hit from the screen was indomethacin, a non-steroidal anti-inflammatory drug. Validation of this molecule in vitro and in cellular efficacy studies in cancer cells provides proof of principle of the approach to pathway down-regulation and a potential optimizable lead compound.

30 April 2019 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
GBGeorge S. Biggs
George S. Biggs
MOMichael J. O'Neill
Michael J. O'Neill
PMPablo Carames Mendez
Pablo Carames Mendez
TSThomas G. Scrase
Thomas G. Scrase
YLYulu Lin
Yulu Lin
PBPaul D. Barker
Paul D. Barker
Speciation of Ru(ii) arene complexes in mixtures of amino acids with coordinating sidechains is easily resolved by 19F NMR.

22 February 2021 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
GBGeorge S. Biggs
George S. Biggs
OKOskar James Klein
Oskar James Klein
SMSarah L. Maslen
Sarah L. Maslen
JSJ. Mark Skehel
J. Mark Skehel
TRTrevor J. Rutherford
Trevor J. Rutherford
PBPaul D. Barker
Paul D. Barker
Many natural metalloenzymes assemble from proteins and biosynthesised complexes, generating potent catalysts by changing metal coordination. Here we adopt the same strategy to generate artificial metalloenzymes (ArMs) using ligand exchange to unmask catalytic activity. By systematically testing RuII(η6‐arene)(bipyridine) complexes designed to facilitate the displacement of functionalised bipyridines, we develop a fast and robust procedure for generating new enzymes via ligand exchange in a protein that has not evolved to bind such a complex. The resulting metal cofactors form peptidic coordination bonds but also retain a non‐biological ligand. Tandem mass spectrometry and 19F NMR spectroscopy were used to characterise the organometallic cofactors and identify the protein‐derived ligands. By introduction of ruthenium cofactors into a 4‐helical bundle, transfer hydrogenation catalysts were generated that displayed a 35‐fold rate increase when compared to the respective small molecule reaction in solution.

29 November 2023 in Physical Chemistry Chemical Physics
Verified
Journal Article
Open access
PDF file
AKAlasdair Donald Keith
Alasdair Donald Keith
ESElizabeth B. Sawyer
Elizabeth B. Sawyer
DCDesmond C. Y. Choy
Desmond C. Y. Choy
YXYuhang Xie
Yuhang Xie
GBGeorge S. Biggs
George S. Biggs
PBPaul D. Barker
Paul D. Barker
To survive, many pathogens extract heme from their host organism and break down the porphyrin scaffold to sequester the Fe2+ ion via a heme oxygenase. Recent studies have revealed that certain pathogens can anaerobically degrade heme. Our own research has shown that one such pathway proceeds via NADH-dependent heme degradation, which has been identified in a family of hemoproteins from a range of bacteria. HemS, from Yersinia enterocolitica, is the main focus of this work, along with HmuS (Yersinia pestis), ChuS (Escherichia coli) and ShuS (Shigella dysenteriae). We combine experiments, Energy Landscape Theory, and a bioinformatic investigation to place these homologues within a wider phylogenetic context. A subset of these hemoproteins are known to bind certain DNA promoter regions, suggesting not only that they can catalytically degrade heme, but that they are also involved in transcriptional modulation responding to heme flux. Many of the bacterial species responsible for these hemoproteins (including those that produce HemS, ChuS and ShuS) are known to specifically target oxygen-depleted regions of the gastrointestinal tract. A deeper understanding of anaerobic heme breakdown processes exploited by these pathogens could therefore prove useful in the development of future strategies for disease prevention.